Francesco Weiss Francesco Weiss

Dr. Francesco Weiss Francesco Weiss

Psychiatry, Azienda Ospedaliera Universitaria Pisana, Pisa, Tuscany, Italy
orcid
Γνῶθι σεαυτόν

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Francesco Weiss Francesco WeissFrancesco Weiss Francesco Weiss
Francesco Weiss Francesco Weiss
MBMargherita Barbuti
Margherita Barbuti
GCGiulia Carignani
Giulia Carignani
ACAlba Calderone
Alba Calderone
FSFerruccio Santini
Ferruccio Santini
Giulio PerugiGiulio Perugi
Giulio Perugi
In the last decades, obesity has become a major concern for clinical and public health. Despite the variety of available treatments, the outcomes remain—by and large—still unsatisfactory, owing to high rates of nonresponse and relapse. Interestingly, obesity is being associated with a growing surge of neuropsychiatric problems, certainly related to the pathogenesis of this condition, and likely to be of great consequence as for its treatment and prognosis. In a neurobiologic direction, a sturdy body of evidence has recently shown that the immune–metabolic–endocrine dyscrasias, notoriously attached to excess body weight/adiposity, affect and impair the morpho-functional integrity of the brain, thus possibly contributing to neuroprogressive/degenerative processes and behavioral deviances. Likewise, in a neuropsychiatric perspective, obesity displays complex associations with mood disorders and affective temperamental dimensions (namely cyclothymia), eating disorders characterized by overeating/binge-eating behaviors, ADHD-related executive dysfunctions, emotional dysregulation and motivational–addictive disturbances. With this review, we attempt to provide the clinician a synoptic, yet exhaustive, tool for a more conscious approach to that subset of this condition, which could be reasonably termed “psychiatric” obesity.

25 January 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Francesco Weiss Francesco WeissFrancesco Weiss Francesco Weiss
Francesco Weiss Francesco Weiss
Anna MagnesaAnna Magnesa
Anna Magnesa
MGMatteo Gambini
Matteo Gambini
RGRiccardo Gurrieri
Riccardo Gurrieri
EAEric Annuzzi
Eric Annuzzi
Donatella MarazzitiDonatella Marazziti
Donatella Marazziti
Background: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still a lively controversy in the medical community as regards the rationale of their employment, specifically their indications and potential dangers. Methods: A comprehensive literature search on “MEDLINE/PubMed” and “Web of Science” was performed from inception to 26 June 2024, cross-checking the obtained references. We included all studies, i.e., both clinical and preclinical, that supplied original data. Results: We initially obtained a total of 1083 entries, 813 from MEDLINE/PubMed and 270 from Web of Science. After duplicate elimination, 903 underwent systematic literature selection. Primary abstract screening yielded a total of 572 candidates for eligibility assessment and excluded 331 entries on formal grounds. Eligibility assessment led to the exclusion of 501 titles. Finally, a total of 70 articles were included in this review. Discussion: Preclinical evidence from genetic expression, histology and behavioral studies is soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, clinical evidence seems to be inferentially in agreement with preclinical findings. However, it is still unclear whether the “neuroplastic boost” induced by classic psychedelics might be dissociable from the psychodysleptic effects, thereby reducing the psychopathological hazards implied by these compounds. Moreover, the fact that the so-called “relaxation of priors” should be unconditionally beneficial appears debatable, and further research should clarify the possible indications and contraindications of psychedelic psychoplastogens within a precision medicine perspective.

1 January 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MBMargherita Barbuti
Margherita Barbuti
GCGiulia Carignani
Giulia Carignani
Francesco Weiss Francesco WeissFrancesco Weiss Francesco Weiss
Francesco Weiss Francesco Weiss
ACAlba Calderone
Alba Calderone
FSFerruccio Santini
Ferruccio Santini
Giulio PerugiGiulio Perugi
Giulio Perugi

19 May 2023 in Bipolar Disorders
Verified
Journal Article
Open access
Francesco Weiss Francesco WeissFrancesco Weiss Francesco Weiss
Francesco Weiss Francesco Weiss
VCValerio Caruso
Valerio Caruso
URUgo De Rosa
Ugo De Rosa
MBMaria Francesca Beatino
Maria Francesca Beatino
MBMargherita Barbuti
Margherita Barbuti
Giulio PerugiGiulio Perugi
Giulio Perugi
Objectives: Glutamatergic transmission and N‐methyl‐D‐aspartate receptors (NMDARs) have been implicated in the pathophysiology schizophrenic spectrum and major depressive disorders. Less is known about the role of NMDARs in bipolar disorder (BD). The present systematic review aimed to investigate the role of NMDARs in BD, along with its possible neurobiological and clinical implications.Methods: We performed a computerized literature research on PubMed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement, using the following string: ((“Bipolar Disorder”[Mesh]) OR (manic‐depressive disorder[Mesh]) OR (“BD”) OR (“MDD”)) AND ((NMDA [Mesh]) OR (N‐methyl‐D‐aspartate) OR (NMDAR[Mesh]) OR (N‐methyl‐D‐aspartate receptor)).Results: Genetic studies yield conflicting results, and the most studied candidate for an association with BD is the GRIN2B gene. Postmortem expression studies (in situ hybridization and autoradiographic and immunological studies) are also contradictory but suggest a reduced activity of NMDARs in the prefrontal, superior temporal cortex, anterior cingulate cortex, and hippocampus.Conclusions: Glutamatergic transmission and NMDARs do not appear to be primarily involved in the pathophysiology of BD, but they might be linked to the severity and chronicity of the disorder. Disease progression could be associated with a long phase of enhanced glutamatergic transmission, with ensuing excitotoxicity and neuronal damage, resulting into a reduced density of functional NMDARs.

1 March 2025 in Life
Verified
Journal Article
Open access
PDF file
FMFederico Mucci
Federico Mucci
Alessandro AroneAlessandro Arone
Alessandro Arone
RGRiccardo Gurrieri
Riccardo Gurrieri
Francesco Weiss Francesco WeissFrancesco Weiss Francesco Weiss
Francesco Weiss Francesco Weiss
GRGerardo Russomanno
Gerardo Russomanno
Donatella MarazzitiDonatella Marazziti
Donatella Marazziti
Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)—such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone—has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. This review attempts to carefully examine the evidence on the neurotrophic properties of TGAs and their role in modulating brain plasticity by analyzing studies published between 2010 and 2024. Although data remain limited and focused primarily on earlier SGAs, emerging findings suggest that some TGAs may exert positive effects on neuroplastic processes, including the modulation of brain-derived neurotrophic factors (BDNFs) and synaptic architecture. However, robust clinical data on their long-term effects and comparative efficacy are lacking; therefore, further research is necessary to validate their role in preventing neurodegenerative changes and improving cognitive outcomes in patients with psychiatric conditions.

19 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CECamilla Elefante
Camilla Elefante
Giulio Emilio BrancatiGiulio Emilio Brancati
Giulio Emilio Brancati
DADonatella Acierno
Donatella Acierno
GPGabriele Pistolesi
Gabriele Pistolesi
SRSara Ricciardulli
Sara Ricciardulli
Giulio PerugiGiulio Perugi
Giulio Perugi
Even though pseudodementia has been historically linked to depression, other psychiatric conditions may cause reversible cognitive alterations. The purpose of this study is to improve our understanding of pseudodementia occurring throughout the entire bipolar spectrum. A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science databases were searched up to March 2023. Fifteen articles on patients with pseudodementia and bipolar disorder (BD), mania, hypomania, or mixed depression have been included. Moreover, seven female patients with mood disorders diagnosed with pseudodementia have been described. According to our research, pseudodementia in patients with BD mostly occurs during a depressive episode. However, pseudodementia has also been observed in the context of manic and mixed states. Psychomotor and psychotic symptoms were commonly associated. The most typical cognitive impairments were disorientation, inattention, and short-term memory deficits. Alterations in neuroimaging were frequently observed. Electroconvulsive therapy and lithium, either alone or in combination with antipsychotics, resulted in the most widely used therapies. Cognitive decline may occur in a substantial proportion of patients. Since pseudodementia can manifest along the entire mood spectrum, it should be taken into consideration as a possible diagnosis in BD patients showing cognitive deficits during manic, mixed, and depressive states.